COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

The substances covered in the IP portfolio include a variety of psychedelic and empathogenic compounds, some of which are prodrugs - pharmacologically inactive compounds which are metabolised inside the body to produce an active drug.